Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3) - ScienceDirect
New Directions in Antiplatelet Therapy | Circulation: Cardiovascular Interventions
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes | Circulation Research
Adenosine-Mediated Effects of Ticagrelor: Evidence and Potential Clinical Relevance - ScienceDirect
Ticagrelor use in Stroke Patients: Past, Present, and Future | VHRM
Ticagrelor: from discovery to Phase III clinical trial | Future Cardiology
Figure I from TICAGRELOR: A NEW REVERSIBLE ORAL ANTIPLATELET AGENT | Semantic Scholar
Frontiers | Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand? | Cell and Developmental Biology
How to manage prasugrel and ticagrelor in daily practice - European Journal of Internal Medicine
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program | Future Cardiology
Mechanisms underlying the probable adenosine-dependent and... | Download Scientific Diagram
Ticagrelor - Wikipedia
New antiplatelet agents : ready for clinical application?
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
Ticagrelor - toward more efficient platelet inhibition and beyon | TCRM
Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week | Journal of the American College of Cardiology
Cardiovascular Medicine - Current trends in dual antiplatelet therapy: a 2017 update
Ticagrelor mechanism of action | Pharmacology, Medical illustration, Medicine studies
Proposed Mechanism of... - Sultania Cardiovascular Sciences | Facebook
Ticagrelor: agonising over its mechanisms of action - ppt download
P2Y12 inhibitors
Mechanism of Action (MOA) | BRILINTA® (ticagrelor) tablets | For HCPs
